PA
AVTX icon

Perceptive Advisors’s Avalo Therapeutics AVTX Stock Holding History

Perceptive Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.06M Buy
219,813
+80,146
+57% +$1.27M 0.06% 95
2026
Q1 		$2.09M Hold
139,667
– – 0.04% 85
2025
Q4 		$2.54M Hold
139,667
– – 0.05% 103
2025
Q3 		$1.78M Hold
139,667
– – 0.05% 82
2025
Q2 		$697K Sell
139,667
-380,333
-73% -$1.78M 0.03% 78
2025
Q1 		$4.17M Buy
+520,000
New +$3.94M 0.15% 70

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Perceptive Advisors's AVTX Position: Q2 2026 in Review

Perceptive Advisors increased its Avalo Therapeutics (AVTX) stake by 57% in Q2 2026, buying an estimated $1.27M and bringing the position to 219,813 shares worth $4.06M. The position accounts for 0.06% of the portfolio, ranked #95.

Perceptive Advisors first reported a position in AVTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.17M in Q1 2025. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Perceptive Advisors held 219,813 shares of Avalo Therapeutics worth $4.06M as of Q2 2026.
  • Perceptive Advisors bought 80,146 Avalo Therapeutics shares in Q2 2026, an estimated $1.27M.
  • Avalo Therapeutics made up 0.06% of Perceptive Advisors's portfolio in Q2 2026, its #95 holding.
  • Perceptive Advisors first reported a position in Avalo Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Perceptive Advisors's Avalo Therapeutics position peaked at $4.17M in Q1 2025.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.